Liquidia Corp
LQDA13.100USD
+0.270+2.10%
Fechamento 06/27, 16:00（ET）Cotações atrasadas em 15 min
1.12BValor de mercado
PerdaP/L TTM
Mais detalhes de Liquidia Corp Empresa
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
Informações da empresa
Código da empresaLQDA
Nome da EmpresaLiquidia Corp
Data de listagemJul 26, 2018
Fundado em2020
CEODr. Roger A. Jeffs, Ph.D.
Número de funcionários157
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 26
Endereço419 Davis Drive
CidadeMORRISVILLE
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal27560
Telefone19193284400
Sitehttps://www.liquidia.com/
Código da empresaLQDA
Data de listagemJul 26, 2018
Fundado em2020
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
2.13M
+1.85%
Mr. Russell Schundler, J.D.
Mr. Russell Schundler, J.D.
General Counsel, Secretary
General Counsel, Secretary
372.72K
+2.59%
Mr. Rajeev Saggar, M.D.
Mr. Rajeev Saggar, M.D.
Chief Medical Officer
Chief Medical Officer
266.92K
+3.92%
Mr. Scott Moomaw
Mr. Scott Moomaw
Chief Commercial Officer
Chief Commercial Officer
216.08K
+4.00%
Mr. Jason Adair
Mr. Jason Adair
Chief Business Officer
Chief Business Officer
161.93K
+5.42%
Mr. Michael Kaseta
Mr. Michael Kaseta
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
146.34K
+10.17%
Mr. Damian Degoa
Mr. Damian Degoa
Independent Director
Independent Director
66.11K
+38.55%
Mr. Arthur S. Kirsch
Mr. Arthur S. Kirsch
Independent Director
Independent Director
50.40K
+57.49%
Dr. Joanna C. Horobin
Dr. Joanna C. Horobin
Independent Director
Independent Director
18.40K
--
Ms. Katherine (Katie) Rielly-Gauvin
Ms. Katherine (Katie) Rielly-Gauvin
Independent Director
Independent Director
18.40K
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
2.13M
+1.85%
Mr. Russell Schundler, J.D.
Mr. Russell Schundler, J.D.
General Counsel, Secretary
General Counsel, Secretary
372.72K
+2.59%
Mr. Rajeev Saggar, M.D.
Mr. Rajeev Saggar, M.D.
Chief Medical Officer
Chief Medical Officer
266.92K
+3.92%
Mr. Scott Moomaw
Mr. Scott Moomaw
Chief Commercial Officer
Chief Commercial Officer
216.08K
+4.00%
Mr. Jason Adair
Mr. Jason Adair
Chief Business Officer
Chief Business Officer
161.93K
+5.42%
Mr. Michael Kaseta
Mr. Michael Kaseta
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
146.34K
+10.17%
Detalhamento da receita
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
14.00M
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 16 de mai
Atualizado em: sex, 16 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Caligan Partners, LP
9.50%
Manning (Paul B.)
7.21%
BlackRock Institutional Trust Company, N.A.
4.91%
Farallon Capital Management, L.L.C.
4.67%
The Vanguard Group, Inc.
4.04%
Other
69.67%
Investidores
Investidores
Proporção
Caligan Partners, LP
9.50%
Manning (Paul B.)
7.21%
BlackRock Institutional Trust Company, N.A.
4.91%
Farallon Capital Management, L.L.C.
4.67%
The Vanguard Group, Inc.
4.04%
Other
69.67%
Tipos de investidores
Investidores
Proporção
Hedge Fund
30.69%
Investment Advisor/Hedge Fund
15.97%
Investment Advisor
12.67%
Individual Investor
11.55%
Research Firm
3.48%
Corporation
2.69%
Private Equity
1.78%
Bank and Trust
0.26%
Pension Fund
0.21%
Other
20.70%
Participação acionária institucional
Atualizado em: ter, 4 de mar
Atualizado em: ter, 4 de mar
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
344
64.23M
75.45%
-9.89M
2024Q4
344
63.62M
75.17%
-10.09M
2024Q3
335
73.31M
89.39%
+16.42M
2024Q2
318
66.67M
87.88%
+4.98M
2024Q1
302
59.34M
79.61%
+7.64M
2023Q4
256
48.15M
70.41%
+4.56M
2023Q3
236
40.52M
62.49%
-5.87M
2023Q2
223
41.12M
63.56%
-6.16M
2023Q1
214
42.01M
65.00%
-5.41M
2022Q4
210
41.20M
63.89%
-7.92M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Caligan Partners, LP
8.12M
9.52%
--
--
Dec 31, 2024
Manning (Paul B.)
6.15M
7.21%
+316.72K
+5.43%
Sep 30, 2024
BlackRock Institutional Trust Company, N.A.
4.18M
4.9%
+416.76K
+11.07%
Dec 31, 2024
Farallon Capital Management, L.L.C.
3.29M
3.86%
--
--
Dec 31, 2024
The Vanguard Group, Inc.
3.55M
4.16%
+115.37K
+3.36%
Dec 31, 2024
Findell Capital Management LLC
3.08M
3.61%
-113.54K
-3.56%
Dec 31, 2024
Opaleye Management Inc.
1.70M
1.99%
--
--
Dec 31, 2024
Jeffs (Roger A)
2.19M
2.56%
+206.98K
+10.46%
Jan 14, 2025
Legend Aggregator LP
1.86M
2.18%
-5.32M
-74.10%
Dec 31, 2024
State Street Global Advisors (US)
1.81M
2.12%
-363.63K
-16.72%
Dec 31, 2024
Ver Mais
ETFs Relacionados
Atualizado em: sex, 6 de jun
Atualizado em: sex, 6 de jun
Nome
Proporção
Invesco Pharmaceuticals ETF
2.76%
Invesco Dorsey Wright Healthcare Momentum ETF
1.97%
SPDR S&P Pharmaceuticals ETF
1.71%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.11%
ALPS Medical Breakthroughs ETF
1.08%
Virtus LifeSci Biotech Clinical Trials ETF
1.01%
iShares U.S. Pharmaceuticals ETF
0.3%
First Trust Small Cap Growth AlphaDEX Fund
0.27%
SPDR S&P Kensho New Economies Composite ETF
0.22%
iShares Micro-Cap ETF
0.21%
Ver Mais
Invesco Pharmaceuticals ETF
Proporção2.76%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporção1.97%
SPDR S&P Pharmaceuticals ETF
Proporção1.71%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporção1.11%
ALPS Medical Breakthroughs ETF
Proporção1.08%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção1.01%
iShares U.S. Pharmaceuticals ETF
Proporção0.3%
First Trust Small Cap Growth AlphaDEX Fund
Proporção0.27%
SPDR S&P Kensho New Economies Composite ETF
Proporção0.22%
iShares Micro-Cap ETF
Proporção0.21%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
